Proviron is an androgenic drug to be taken orally. The presence of C-1 methyl group in the structure of the drug determines the special properties of this steroid: unlike testosterone and its derivatives used for androgenic therapy, it is not metabolised into estrogen.
This difference fully explains the observation that in the standard therapeutic dose used in healthy men, Proviron® does not cause a significant inhibition of the release of gonadotropins from the pituitary. Therefore, Proviron® (1) has no effect on spermatogenesis and (2) does not affect the body's own testosterone production, which distinguishes it from other androgens that replace testosterone levels with inhibited production of endogenous androgens.
Unlike other androgens for ingestion, there is good tolerance of Proviron® on the liver side, which is probably due to the absence of alkyl substitution in the C-17 position of the steroid nucleus.
Indications for use
- androgen deficiency or male infertility associated with primary or secondary male hypogonadism.
Method of use and doses
3 or 4 tablets daily for several months, followed by maintenance therapy: 2-3 tablets (50-75mg) daily.
not recommended for children.
In some cases
- frequent or very prolonged erections
- prostate cancer (as androgens can stimulate the growth of an existing tumour)
- liver tumours at present or in history
- Hypersensitivity to the meshedrillon or to any other site
to a drug component
Androgens should not be taken by healthy individuals to strengthen muscles or increase the body's overall physical functionality.
During treatment, it is recommended to perform regular prostate studies to eliminate prostate cancer.
If there are individual cases of frequent or very prolonged erections, the dose should be reduced or treatment discontinued to avoid complications due to a prolonged erection.
In rare cases, against the background of the use of substances with hormonal activity, including those contained in the preparation Proviron®, benign tumours have been observed, and even less often - malignant liver tumours, which in some cases may lead to life-threatening intra-abdominal bleeding. In the event of severe abdominal pain, enlargement of the liver or signs of intra-abdominal bleeding, the presence of a liver tumour should be taken into account in differential diagnosis.
Patients with hereditary disorders, such as fructose intolerance, deficiency of the enzyme Lapp-lactase or glucose-galactose malabsorption, should consider the amount of lactose contained in Proviron®.
Peculiarities of the effect of the medicinal product on the ability to drive vehicles and potentially dangerous mechanisms.
|Active ingredient, mg||25|
|1 tablet, mg||25|
|Release form||Blister (10 tablets), Packing (2 blisters)|
|Blisters, tablets||2, 10|